Adage Capital Partners Gp, L.L.C. Neurocrine Biosciences Inc Transaction History

Adage Capital Partners Gp, L.L.C.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$75.79 - $100.07 $1.52 Million - $2 Million	20,000 Added 23.53%	105,000 $10.2 Million
Q1 2022 May 16, 2022	SELL	$72.45 - $94.81 $25.5 Million - $33.4 Million	-352,000 Reduced 80.55%	85,000 $7.97 Million
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $34.8 Million - $46.4 Million	437,000 New	437,000 $37.2 Million
Q4 2019 Feb 14, 2020	SELL	$86.8 - $118.57 $5.38 Million - $7.35 Million	-62,000 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$83.82 - $101.5 $5.2 Million - $6.29 Million	62,000 New	62,000 $5.59 Million
Q1 2019 May 15, 2019	SELL	$69.31 - $91.53 $554,480 - $732,240	-8,000 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$68.32 - $124.36 $1.23 Million - $2.24 Million	-18,000 Reduced 69.23%	8,000 $571,000
Q3 2018 Nov 14, 2018	SELL	$98.88 - $125.85 $12.5 Million - $15.9 Million	-126,000 Reduced 82.89%	26,000 $3.2 Million
Q2 2018 Aug 14, 2018	BUY	$75.3 - $105.99 $11.4 Million - $16.1 Million	152,000 New	152,000 $14.9 Million

638

93.8M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $14.5B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.